"ALMR is promising long-term in proteomics-enabled early disease detection, but I’m bearish on the stock as an investment right now because it’s still unprofitable (nearly $30M net loss) with limited margin for error at roughly a 21 price-to-sales multiple and a $1.6B+ market cap."
"7 Stocks Cathie Wood is Buying Right Now!"